223
Participants
Start Date
February 28, 2001
Primary Completion Date
October 31, 2001
Study Completion Date
October 31, 2001
liraglutide
Injected subcutaneously once daily
metformin
1000 mg twice daily, administered orally
Novo Nordisk Investigational Site, Richmond
Novo Nordisk Investigational Site, Charleston
Novo Nordisk Investigational Site, Durham
Novo Nordisk Investigational Site, Charlotte
Novo Nordisk Investigational Site, Jacksonville
Novo Nordisk Investigational Site, Titusville
Novo Nordisk Investigational Site, Melbourne
Novo Nordisk Investigational Site, Pembroke Pines
Novo Nordisk Investigational Site, Miami
Novo Nordisk Investigational Site, West Palm Beach
Novo Nordisk Investigational Site, St. Petersburg
Novo Nordisk Investigational Site, Ocala
Novo Nordisk Investigational Site, Vestavia Hills
Novo Nordisk Investigational Site, Chattanooga
Novo Nordisk Investigational Site, Duluth
Novo Nordisk Investigational Site, Chicago
Novo Nordisk Investigational Site, Springfield
Novo Nordisk Investigational Site, St Louis
Novo Nordisk Investigational Site, St Louis
Novo Nordisk Investigational Site, Carlisle
Novo Nordisk Investigational Site, Jonesboro
Novo Nordisk Investigational Site, Oklahoma City
Novo Nordisk Investigational Site, Dallas
Novo Nordisk Investigational Site, Dallas
Novo Nordisk Investigational Site, San Antonio
Novo Nordisk Investigational Site, San Antonio
Novo Nordisk Investigational Site, Corpus Christi
Novo Nordisk Investigational Site, Salt Lake City
Novo Nordisk Investigational Site, Tucson
Novo Nordisk Investigational Site, Alhambra
Novo Nordisk Investigational Site, Mission Viejo
Novo Nordisk Investigational Site, Walnut Creek
Novo Nordisk Investigational Site, Edmonds
Novo Nordisk Investigational Site, Renton
Novo Nordisk Investigational Site, Tacoma
Novo Nordisk Investigational Site, Trumbull
Novo Nordisk Investigational Site, Worcester
Novo Nordisk Investigational Site, North Plainfield
Novo Nordisk Investigational Site, Edmonds
Lead Sponsor
Novo Nordisk A/S
INDUSTRY